New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced breast cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer is HER2-positive (tested with a biopsy score of 3+ or 2+ with a positive FISH test).
- You have already been treated with trastuzumab (Herceptin or a biosimilar) or inetetamab, and your cancer progressed or came back during or within 12 months after treatment.
- You have been treated with a taxane chemotherapy (like paclitaxel or docetaxel).
- You have at least one measurable tumor outside the brain that can be seen on scans like CT or MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
This trial tests a new combination of two study drugs (JSKN016 and D-0502) for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has grown after standard hormonal and CDK4/6 inhibitor treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This study tests an investigational drug called KJ015 for people with HER2-positive solid tumors (cancer that has a specific protein on its surface). The goal is to see if the drug is safe and effective in treating your type of cancer.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.